

May 3, 2013



# Navidea Biopharmaceuticals to Announce First Quarter 2013 Financial Results Pre-market on Wednesday, May 8, 2013

**- Conference call with investment community to follow -**

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the first quarter of 2013, on Wednesday, May 8, 2013 before the market opens. The announcement will be followed by a conference call with the investment community, also on Wednesday, May 8, 2013, at 8:30 a.m. EDT, to provide a business update and discuss the Company's financial and operational results.

Investors and the public are invited to listen live to the call. If you are unable to join the live call, an archived version will be available until May 22, 2013. The conference call can be accessed as follows:

## CONFERENCE CALL INFORMATION

### TO PARTICIPATE LIVE:

Date: May 8, 2013

Time: 8:30 a.m. EDT

Toll-free (U.S.) Dial in # : (877) 407-8031

International Dial in # : (201) 689-8031

### TO LISTEN TO A REPLAY:

Available until: May 22, 2013

Toll-free (U.S.) Dial in # : (877) 660-6853

International Dial in # : (201) 612-7415

Replay passcode:

Account #: 268

Conference ID # 414024

## About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent

platforms – Lymphoseek<sup>®</sup>, NAV4694, NAV5001 and RIGScan<sup>™</sup> – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit [www.navidea.com](http://www.navidea.com).

*Navidea Biopharmaceuticals*

*Brent Larson, 614-822-2330*

*Sr. VP & CFO*

*or*

*Investor Relations:*

*Stern Investor Relations, Inc.*

*Beth DelGiaccio, 212-362-1200*

Source: Navidea Biopharmaceuticals, Inc.